Rapid Uptake Products (RUPs)

The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date. Click here to read the technical notes.

The HIN will be supporting the adoption of the following innovations through the RUP Programme during 2021:

  1. Lipid Management : High Intensity Statins, Ezetimibe and PCSK9 inhibitors
  2. Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
  3. Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

Applications for Pathway Transformation Funding to help providers overcome practical obstacles to introducing Tamoxifen are open from 14 June 2021 until midday, 9 July 2021. Click here to find out more about applying.

We're here to help

Interested in adopting a RUP innovation? Please contact hin.nhsaac@nhs.net.

Get in touch